Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12...4647484950515253545556...266267»
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) -  Mar 22, 2023   
    P2/3,  N=600, Recruiting, 
    Trial completion date: Nov 2023 --> Jun 2033 | Trial primary completion date: Nov 2023 --> Jun 2033
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    New P2 trial, Checkpoint inhibition:  Cryoablation+Ipilimumab+Nivolumab in Melanoma (clinicaltrials.gov) -  Mar 22, 2023   
    P2,  N=37, Not yet recruiting, 
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, HEOR:  Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. (Pubmed Central) -  Mar 21, 2023   
    Amid the evolving landscape of systemic therapy for advanced melanoma, nivolumab monotherapy emerged as the most used and least costly systemic treatment from 2016 to 2020. Its sharp increase in use in 2018 and lower costs relative to pembrolizumab may in part be due to earlier adoption of less frequent dosing intervals.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, PD(L)-1 Biomarker, IO biomarker:  Undifferentiated pleomorphic sarcoma of the breast with neoplastic fever: case report and genomic characterization. (Pubmed Central) -  Mar 21, 2023   
    In patients with resected stage IIIB-C cutaneous melanoma in this ITC, nivolumab improved RFS versus placebo and ipilimumab, and OS versus placebo after post-recurrence survival adjustment. We describe here the first case of UPS-NF of the breast, which shows great clinical and histopathologic resemblances to previously reported UPS-NF of other anatomic localizations.
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Review, Journal, Adverse events, Checkpoint inhibition:  Mucocutaneous adverse events to immune checkpoint inhibitors. (Pubmed Central) -  Mar 21, 2023   
    Since the approval of ipilimumab in 2011, a total of nine ICIs have gained indications for various solid and hematologic malignancies...Even though less than 3% of cutaneous irAEs (irCAEs) are classified as grade 3 or higher events, irCAEs can greatly impact quality of life. Appropriate management of irCAEs is critical to avoid unwarranted interruptions or discontinuation of lifesaving immunotherapy.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Retrospective data, Journal, Checkpoint inhibition, Metastases:  Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-na (Pubmed Central) -  Mar 21, 2023   
    Appropriate management of irCAEs is critical to avoid unwarranted interruptions or discontinuation of lifesaving immunotherapy. Randomized controlled trials (RCTs) on therapies recommended by the latest EAU and ESMO guidelines for treatment-na
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal:  Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. (Pubmed Central) -  Mar 20, 2023   
    At 2-year minimum follow-up, first-line nivolumab plus ipilimumab with chemotherapy reduced the risk of definitive deterioration in disease-related symptom burden and health-related quality of life versus chemotherapy and maintained QoL in patients with metastatic non-small cell lung cancer. Nivolumab plus cabozantinib with or without ipilimumab showed encouraging preliminary antitumor activity and had consistent safety profiles with those established for the individual drugs in patients with advanced hepatocellular carcinoma.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment closed:  SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov) -  Mar 20, 2023   
    P2,  N=818, Active, not recruiting, 
    Nivolumab plus cabozantinib with or without ipilimumab showed encouraging preliminary antitumor activity and had consistent safety profiles with those established for the individual drugs in patients with advanced hepatocellular carcinoma. Recruiting --> Active, not recruiting
  • ||||||||||  Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases:  Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. (Pubmed Central) -  Mar 14, 2023   
    The seven treatment drug strategies included atezolizumab + bevacizumab, avelumab + axitinib, pembrolizumab + axitinib, nivolumab + ipilimumab (NI), nivolumab + cabozantinib, lenvatinib + pembrolizumab, and sunitinib...In sensitivity analyses, this ICER fell below $150,000 USD/QALY if the initial 4-month cost of NI decreased by 22%-38%. NI was the most effective combination for mRCC, but at a willingness-to-pay threshold of $150,000 USD/QALY, sunitinib was the most cost-effective approach.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    An angiogenic target of immune exclusion with checkpoint blockade in melanoma (Section 4; Poster Board #6) -  Mar 14, 2023 - Abstract #AACR2023AACR_8828;    
    Tumor biopsies from a phase I study with 46 advanced melanoma patients treated with Ipilimumab and Bevacizumab combination (Ipi-Bev) therapy, revealed activated endothelium accompanied by lymphocyte infiltration...The anti-EDIL3 response was also observed to be significantly (p=0.03) related to Ipi-Bev treatment when compared with patients treated with Ipilimumab alone, anti-PD1 therapy alone, or the combination of Ipilimumab and Nivolumab in a combined analysis...This study develops EDIL3 as a potential target to enhance cytotoxic immune responses and improve the outcomes of combination immune therapy. Studies are ongoing for targeted inhibition of EDIL3 with implications for therapeutic application to promote anti-tumor immunity.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Manipulation of mitochondrial metabolism, through SIRT3 agonists, in a novel immunoreactive melanoma organoids model (Section 11; Poster Board #16) -  Mar 14, 2023 - Abstract #AACR2023AACR_8685;    
    Further studies will aim to validate these results in immunoreactive organoids from both mice and human patients. Our studies will shed light on the immune and metabolic axes and the use of specific agonists to develop new immune therapy treatment strategies for melanoma.
  • ||||||||||  Investigating the effect of immune checkpoint inhibitors (ICI) on ovarian function in young patients with melanoma (Section 38; Poster Board #16) -  Mar 14, 2023 - Abstract #AACR2023AACR_8220;    
    While these results are preliminary, when considered in conjunction with recent pre-clinical data showing changes within the ovaries after ICI treatment, fertility consultation should be considered for young women prior to ICI initiation. We are investigating associations between AMH, AFC, age, ICI exposure, and future pregnancies in an ongoing prospective study.
  • ||||||||||  Transcriptomic biomarkers of immunotherapy response in solid tumors (Section 38; Poster Board #9) -  Mar 14, 2023 - Abstract #AACR2023AACR_8214;    
    An integrated database and an online platform were set up to validate potential biomarkers of immunotherapy response in a sizeable cohort of cancer samples from multiple tumor types. By using the direction of expression change as a filter, we have identified the most promising biomarker candidates.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Spatial relationships in the tumor microenvironment predict response to immune checkpoint inhibitors in urothelial and head and neck cancer (Tangerine Ballroom 1 (WF1) - Convention Center) -  Mar 14, 2023 - Abstract #AACR2023AACR_7968;    
    P1/2, P1b
    We created a framework to quantify, study, interpret and analyze spatial relationships in the TME and illustrated its superior clinical relevance compared to density metrics for predicting ICI treatment response. Our findings emphasize the importance of spatial relationships in the TME for response and suggest that proximity between either macrophages or CD8+ T-cells to cancer cells are candidate biomarkers for ICI response.
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    An integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma (Valencia A - Convention Center) -  Mar 14, 2023 - Abstract #AACR2023AACR_7849;    
    Introduction CTLA4 blockade with ipilimumab was more favorable than interferon-?2b (IFN) in high-risk melanoma in phase adjuvant III trial E1609...In addition, we determined that: i) higher age and higher L-IPI7 risk score identified patients with the worst OS and RFS And ii) female patients with a low L-IPI7 risk scores had a better OS and RFS.Conclusions We developed a broadly applicable model based on LASSO Cox Regression predictive of adjuvant ipi treatment outcomes in melanoma. Our L-IPI7 score based on expression of CXCL9, CD8A, CXCL10, INPP5D, IDO1, IGKC, IL2RB effectively predicts survival, with interactions with age, gender and on-treatment development of colitis.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses (Chapin Theater - Convention Center) -  Mar 14, 2023 - Abstract #AACR2023AACR_7821;    
    This exploratory analysis suggests that there are patient subgroups with GC/GEJC/EAC that may benefit from dual immune checkpoint blockade. Clinical utility of these biomarkers should be prospectively validated in future trials.Overall survivalAll randomized patientsHR (95% CI)0.89 (0.77-1.03)All evaluable HR (95% CI)High, n (%) HR (95% CI)Medium, n (%) HR (95% CI)Low, n (%) HR (95% CI)TMB (n = 366)0.81 (0.65-1.00)21 (6) 0.31 (0.10-0.95)-345 (94) 0.87 (0.70-1.09)GES (n = 402)Chemokine0.82 (0.67-1.01)134 (33) 0.59 (0.40-0.86)134 (33) 0.92 (0.65-1.32)134 (33) 0.98 (0.68-1.40)Treg134 (33) 0.59 (0.41-0.86)134 (33) 0.91 (0.64-1.30)134 (33) 1.07 (0.75-1.52)Fibroblast134 (33) 0.98 (0.69-1.40)134 (33) 0.94 (0.66-1.35)134 (33) 0.63 (0.43-0.91)Endothelial134 (33) 0.97 (0.68-1.38)134 (33) 0.94 (0.65-1.34)134 (33) 0.65 (0.45-0.94)OS HR data are unstratified for NIVO + IPI vs chemo.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library (Section 6; Poster Board #22) -  Mar 14, 2023 - Abstract #AACR2023AACR_7743;    
    This library of MPM PDXs, the largest to date, effectively mimics human disease and provides unprecedented insight into the genomic, transcriptomic, and protein landscape of MPM. These PDX models will inform future clinical investigations and provide an important new preclinical resource.